Outrun Therapeutics Advances First-in-Class E6AP Inhibitor for HPV-Positive Head and Neck Cancer
Key Insights
Outrun Therapeutics (search) has selected a first-in-class E6AP ubiquitin ligase inhibitor (search) as its lead programme for treating HPV-positive head and neck cancer (search), with clinical entry expected in 2027.
The novel therapeutic strategy aims to stabilize tumor suppressor proteins (search) by inhibiting E6AP (search), targeting an underserved patient population representing 4.5% of cancers worldwide.
The company has assembled a world-class Scientific Advisory Board including renowned experts in E3 ligase biology and head and neck cancer (search) to guide clinical development.
Outrun Therapeutics (search) has unveiled its lead therapeutic programme targeting HPV-positive head and neck cancer (search) through a first-in-class E6AP (search) ubiquitin ligase inhibition strategy. The Scotland-based biotech company announced the selection alongside the formation of a Scientific Advisory Board comprising international experts in E3 ligase biology and head and neck cancer (search).
The programme represents a novel approach to cancer (search) treatment by directly stabilizing tumor suppressor protein levels through E6AP (search) inhibition. E6AP is an E3 ubiquitin ligase that regulates the expression of key tumor suppressor proteins (search) in HPV-positive cancers (search), making its inhibition a potentially transformative therapeutic strategy.
Preclinical Progress and Clinical Timeline
The lead programme has demonstrated strong proof of mechanism in both in vitro and in vivo studies, according to the company. Outrun expects to announce a development candidate later this year, with clinical entry anticipated in 2027.
The therapeutic approach emerged from Outrun's proprietary XL discovery platform, which has been used to profile over 45 diverse E3 ligases (search) across oncology, neurology, cardiovascular, and autoimmune diseases. This platform enabled the identification of the E6AP inhibitor (search) strategy from the company's first-in-class therapeutic pipeline.
Market Opportunity and Patient Impact
HPV-positive cancers (search) account for approximately 4.5% of cancers worldwide, representing a significant unmet medical need. The global market size for HPV-positive cancer (search) treatments is expected to exceed $14 billion by 2031, highlighting the commercial potential of effective therapies in this space.
"This is a massively underserved patient population, and we are confident that our novel approach to protein stabilisation offers a breakthrough route to bringing meaningful treatments to those in need," said Dr. Tony Johnson, Board Chair and Interim CEO of Outrun Therapeutics (search).
Scientific Advisory Board Formation
To support the programme's advancement, Outrun has appointed five leading experts to its Scientific Advisory Board:
Professor Glenn Hanna from Dana-Farber Cancer Institute and Harvard Medical School brings expertise in head and neck cancer (search) precision medicine and immunotherapy. As Director of the Center for Cancer (search) Therapeutic Innovation, he focuses on molecular and immunologic biomarker discovery for HPV-associated malignancies.
Professor Kevin Harrington from the Institute of Cancer Research is internationally recognized for developing targeted therapies including oncolytic viruses and immune checkpoint inhibitors for head and neck cancer (search). He leads translational research bridging laboratory innovation with clinical application.
Professor Gigi Lozano from MD Anderson Cancer Center is renowned for pioneering research on the p53 tumor suppressor pathway. Her laboratory was among the first to demonstrate p53's function as a transcriptional activator, and she is a member of the National Academy of Sciences.
Dr. Donald Ogilvie, formerly of AstraZeneca and Cancer Research UK Manchester Institute, brings two decades of oncology drug discovery and early clinical development experience. He now serves as an independent scientific consultant for cancer (search) drug discovery initiatives.
Professor Martin Scheffner from the University of Konstanz (search) is a molecular biologist known for co-discovering the role of E6AP (search) ubiquitin-protein ligase in targeting p53 for degradation—a key insight into HPV's contribution to cancer (search) development.
These experts join Professor Satpal Virdee, Outrun's Founder and Chair of the SAB, who noted that "attracting such high-profile and experienced figures to our SAB is tremendous validation of the novel nature of our technology."
Technology Platform and Pipeline
Outrun's XL discovery platform enables identification of E3 ligase modulators whose dysregulation contributes to multiple diseases. Beyond the lead HPV-positive head and neck cancer (search) programme, the company's pipeline includes additional programmes in oncology, cardiovascular, and neurology indications.
The company is backed by leading life-science investors M Ventures (search) and MP Healthcare Venture Management (search), providing financial support for advancing its protein-stabilizing therapeutic approach.
Professor Virdee emphasized that the SAB's expertise will be "invaluable as we develop the translational strategy, clinical design, and biomarker validation to support our goal of establishing efficacy and differentiation in the HPV-induced head and neck cancer (search) field, and transition to a clinical stage company."